Literature DB >> 11436179

Sulfate could mediate the therapeutic effect of glucosamine sulfate.

L J Hoffer1, L N Kaplan, M J Hamadeh, A C Grigoriu, M Baron.   

Abstract

Glucosamine sulfate is a controversial osteoarthritis remedy that is presumed to stimulate articular cartilage glycosaminoglycan synthesis by increasing glucosamine concentrations in the joint space. However, this is not plausible because even large oral doses of the product have no effect on serum glucosamine concentrations. We propose instead that sulfate could mediate the clinical benefit attributed to this treatment. Sulfate is required for glycosaminoglycan synthesis, and unlike glucosamine, its serum level can be modified by dietary and other factors. In this study, we tested whether oral glucosamine sulfate increases serum sulfate concentrations and whether the sulfate concentration in the synovial fluid reflects that in the serum. The serum sulfate concentration of 7 normal subjects was 331 +/- 21 micromol/L before ingestion of 1.0 g glucosamine sulfate and 375 +/- 17 micromol/L 3 hours after (P <.05). Serum sulfate concentrations decreased from 325 +/- 19 to 290 +/- 19 micromol/L when the same dose of glucosamine sulfate was ingested with 1.0 g of the analgesic drug acetaminophen, which is largely metabolized by sulfation (P <.05). Unlike glucosamine sulfate, oral sodium sulfate did not significantly increase the serum sulfate concentration. Synovial fluid and serum sulfate concentrations were closely similar when measured in 15 patients undergoing diagnostic needle aspiration of a knee effusion (r =.99, slope =.97, P <.0001). These results do not prove that glucosamine sulfate improves osteoarthritis, but considered with other data, they do provide a plausible biochemical mechanism for its reported beneficial effects. This hypothesis is clinically relevant because it predicts that nonsulfate salts of glucosamine will be ineffective and that renal function, diet, and concurrent acetaminophen therapy could confound clinical trials of this therapy. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11436179     DOI: 10.1053/meta.2001.24201

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  8 in total

1.  The efficacy and tolerability of glucosamine sulfate in the treatment of knee osteoarthritis: A randomized, double-blind, placebo-controlled trial.

Authors:  Nicola Giordano; Antonella Fioravanti; Panagiotis Papakostas; Antonio Montella; Giorgio Giorgi; Ranuccio Nuti
Journal:  Curr Ther Res Clin Exp       Date:  2009-06

2.  Sulphate and osteoarthritis: decrease of serum sulphate levels by an additional 3-h fast and a 3-h glucose tolerance test after an overnight fast.

Authors:  C M Blinn; B A Biggee; T E McAlindon; M Nuite; J E Silbert
Journal:  Ann Rheum Dis       Date:  2006-09       Impact factor: 19.103

3.  Changes in serum levels of glucosamine and sulphate after ingestion of glucosamine sulphate with and without simultaneous ingestion of glucose.

Authors:  Beth A Biggee; Christina M Blinn; Melynn Nuite; Timothy E McAlindon; Jeremiah E Silbert
Journal:  Ann Rheum Dis       Date:  2007-10       Impact factor: 19.103

Review 4.  Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis.

Authors:  Olivier Bruyere; Jean-Yves Reginster
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

5.  Use of alternative medicines by patients with OA that adversely interact with commonly prescribed medications.

Authors:  Jacquelyn Marsh; Christine Hager; Tom Havey; Sheila Sprague; Mohit Bhandari; Dianne Bryant
Journal:  Clin Orthop Relat Res       Date:  2009-03-03       Impact factor: 4.176

6.  Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties.

Authors:  Lucio C Rovati; Federica Girolami; Stefano Persiani
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-06       Impact factor: 5.346

Review 7.  Role of glucosamine in the treatment for osteoarthritis.

Authors:  Jean-Yves Reginster; Audrey Neuprez; Marie-Paule Lecart; Nathalie Sarlet; Olivier Bruyere
Journal:  Rheumatol Int       Date:  2012-03-30       Impact factor: 2.631

8.  Nonsteroidal anti-inflammatory drugs modulate cellular glycosaminoglycan synthesis by affecting EGFR and PI3K signaling pathways.

Authors:  Paweł Mozolewski; Marta Moskot; Joanna Jakóbkiewicz-Banecka; Grzegorz Węgrzyn; Katarzyna Bocheńska; Bogdan Banecki; Magdalena Gabig-Cimińska
Journal:  Sci Rep       Date:  2017-02-27       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.